Methylphenidate prescribing across the NHS.
Methylphenidate is the ADHD wave in numbers: 2.1m items in the year to April 2026, growth that shows no sign of an inflection, briefly interrupted by the supply failures of 2023-24. Diagnosis capacity, not clinical demand, is the constraint everyone in this market watches.
The NHS in England dispensed 2,254,190 prescription items of Methylphenidate in the 12 months to July 2026, across primary care and hospitals.
Spending on Methylphenidate over those 12 months was £69.4m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were up 23.6% on the previous 12 months.
97% of Methylphenidate volume moved through primary care and 3% through hospital pharmacies.
Methylphenidate is the largest of 8 chemical substances in CNS Stimulants and drugs used for ADHD (BNF 4.4), by items dispensed.
Among Integrated Care Boards, NHS West and North London ICB dispensed the highest volume of Methylphenidate.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.
| Month | Items | Spend (NIC) |
|---|---|---|
| July 2026 | 225,024 | £6.8m |
| June 2026 | 219,615 | £6.6m |
| May 2026 | 204,613 | £6.2m |
| April 2026 | 197,255 | £6.0m |
| March 2026 | 199,166 | £6.0m |
| February 2026 | 175,832 | £5.3m |
| January 2026 | 187,428 | £5.7m |
| December 2025 | 183,298 | £5.7m |
| November 2025 | 167,133 | £5.2m |
| October 2025 | 175,683 | £5.5m |
| September 2025 | 170,219 | £5.4m |
| August 2025 | 148,924 | £4.8m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
50.6% of its class.
Methylphenidate is the largest of 8 chemical substances in CNS Stimulants and drugs used for ADHD (BNF 4.4), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
27 suppliers hold a live methylphenidate listing, across 140 packs.
A A H Pharmaceuticals Ltd, Accord-UK Ltd, Advanz Pharma, Alliance Healthcare (Distribution) Ltd, Consilient Health Ltd, CST Pharma Ltd, Drug Tariff Special Order, Ethypharm UK Ltd, Exeltis UK Ltd, Flynn Pharma Ltd, Genesis Pharmaceuticals Ltd, Imported (United States), InfectoPharm Ltd, Janssen-Cilag Ltd, Kent Pharma (UK) Ltd, Medice UK Ltd, Medihealth (Northern) Ltd, Necessity Supplies Ltd, Neuraxpharm UK Ltd, Pilsco Ltd, Sandoz Ltd, Special Order, Strides Pharma UK Ltd, Takeda UK Ltd, Teva UK Ltd, Viatris UK Healthcare Ltd, Zentiva Pharma UK Ltd. In the last twelve months 0 packs were listed and 6 discontinued. Every pack, its GTIN and published list price, and each week's changes are in the full report.
A listing in the NHS Dictionary of Medicines and Devices means a product may be supplied. It says nothing about sales or market share, and the list price is the reimbursement price, not what any buyer pays. Contains information from dm+d 10.1.0, published by the NHS Business Services Authority under the Open Government Licence v3.0.
248,225 people in England had at least one methylphenidate item prescribed in primary care in 2025/26, 8.5 items each. Source: NHSBSA Medicines Used in Mental Health, England, official statistics, OGL v3.0. Identified patients only.
Methylphenidate across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much methylphenidate its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Methylphenidate is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS West and North London ICB 203k
- 2 NHS Cheshire and Merseyside ICB 154k
- 3 NHS Surrey and Sussex ICB 127k
- – + 33 more. See the full 36-ICB table. See all →
- 1 NHS West and North London ICB +127.4%
- 2 NHS Cornwall and the Isles of Scilly ICB +67.6%
- 3 NHS Birmingham and Solihull ICB +63.6%
- – + 33 more. See every ICB, ranked. See all →
- 1 Methylphenidate 10mg tablets 10%
- 2 Methylphenidate 5mg tablets 8%
- 3 Medikinet XL 20mg capsules 6%
- – + 3 more. See every strength and pack. See all →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 2.3m | July 2026 |
| Scotland | 224k | June 2026 |
| Northern Ireland | 67k | May 2026 |
| Wales | 69k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.
What open data won't tell you about methylphenidate.
Prescribing follows diagnosis, and the waiting lists that gate diagnosis are the real driver here; none of that queue is visible in dispensing data.
Asked and answered.
Is methylphenidate prescribing rising or falling in the NHS?
Rising. England dispensed 2,254,190 items of Methylphenidate in the 12 months to July 2026, up 23.6% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on methylphenidate?
£69.4m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is methylphenidate prescribed most?
By raw volume, NHS West and North London ICB dispensed the most methylphenidate in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.
Related pages.
See the full molecule directory, or read about the data and pricing.
Track methylphenidate like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Methylphenidate for you.